
Giacomo Caldarola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6624641/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Drug Survival of IL-12/23, IL-17 and IL-23 InhibitorsÂfor Psoriasis Treatment: A Retrospective Multi-Country, Multicentric Cohort Study. American Journal of Clinical Dermatology, 2021, 22, 567-579.	3.3	65
2	Dermoscopy of Cutaneous Sarcoidosis. Dermatology, 2010, 221, 51-54.	0.9	60
3	Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation. Expert Opinion on Biological Therapy, 2018, 18, 727-735.	1.4	52
4	IgC autoantibody reactivity against bullous pemphigoid (BP) 180 and BP230 in elderly patients with pruritic dermatoses. British Journal of Dermatology, 2009, 161, 306-312.	1.4	50
5	Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature. Expert Opinion on Biological Therapy, 2020, 20, 665-672.	1.4	49
6	Tacrolimus 0.1% ointment in nail psoriasis: a randomized controlled openâ€ l abel study. Journal of the European Academy of Dermatology and Venereology, 2013, 27, 1003-1006.	1.3	43
7	Usefulness of Ultrasound Imaging in Detecting Psoriatic Arthritis of Fingers and Toes in Patients with Psoriasis. Clinical and Developmental Immunology, 2011, 2011, 1-5.	3.3	42
8	lgE recognition of bullous pemphigoid (BP)180 and BP230 in BP patients and elderly individuals with pruritic dermatoses. Clinical Immunology, 2012, 143, 236-245.	1.4	40
9	Exacerbation of pemphigus after influenza vaccination. Clinical and Experimental Dermatology, 2008, 33, 718-720.	0.6	38
10	Melanoma and non-melanoma skin cancer in psoriatic patients treated with high-dose phototherapy. Journal of Dermatological Treatment, 2016, 27, 443-447.	1.1	36
11	Ixekizumab Effectiveness and Safety in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Multicenter, Retrospective Observational Study. American Journal of Clinical Dermatology, 2020, 21, 441-447.	3.3	33
12	Combined treatment with etanercept 50Âmg once weekly and narrow-band ultraviolet B phototherapy in chronic plaque psoriasis. European Journal of Dermatology, 2011, 21, 568-572.	0.3	32
13	Untreated Psoriasis Impairs Male Fertility: A Case-Control Study. Dermatology, 2017, 233, 170-174.	0.9	32
14	Lichenoid reaction induced by adalimumab. Journal of the European Academy of Dermatology and Venereology, 2008, 22, 626-627.	1.3	31
15	Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World Study. Clinical Drug Investigation, 2021, 41, 917-925.	1.1	31
16	Dermoscopy of Necrobiosis Lipoidica and Granuloma Annulare. Dermatology, 2013, 226, 319-323.	0.9	30
17	<scp>TNF</scp> â€elpha gene polymorphisms can help to predict response to etanercept in psoriatic patients. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1786-1790.	1.3	30
18	TNFα and its Receptors in Psoriatic Skin, before and after Treatment with Etanercept. International Journal of Immunopathology and Pharmacology, 2009, 22, 961-966.	1.0	29

GIACOMO CALDAROLA

#	Article	IF	CITATIONS
19	Clinical, histopathological, and immunological evaluation of a series of patients with erythema nodosum. International Journal of Dermatology, 2016, 55, e289-94.	0.5	28
20	Management of patients with atopic dermatitis undergoing systemic therapy during COVIDâ€19 pandemic in Italy: Data from the DAâ€COVIDâ€19 registry. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1813-1824.	2.7	28
21	Herpes simplex virus infection in pemphigus vulgaris: clinical and immunological considerations. European Journal of Dermatology, 2008, 18, 440-3.	0.3	28
22	Safety of etanercept in patients with psoriasis and hepatitis C virus assessed by liver histopathology: Preliminary data. Journal of the American Academy of Dermatology, 2010, 62, 1067-1069.e2.	0.6	25
23	New onset of remitting seronegative symmetrical synovitis with pitting oedema and palmoplantar psoriasis flareâ€up after Sars ovâ€2 vaccination. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e727-e729.	1.3	25
24	Infliximab monotherapy in Neuro-Behçet's disease: Four year follow-up in a long-standing case resistant to conventional therapies. Journal of Neuroimmunology, 2011, 239, 105-107.	1.1	23
25	Psoriatic patients have an increased risk of polycystic ovary syndrome: results of a cross-sectional analysis. Fertility and Sterility, 2013, 99, 936-942.	0.5	23
26	A case of guttate psoriasis during treatment with dupilumab. Dermatologic Therapy, 2019, 32, e12998.	0.8	22
27	Clinical predictors of nonresponse to anti-TNF-α agents in psoriatic patients: A retrospective study. Dermatologic Therapy, 2016, 29, 372-376.	0.8	21
28	Living with Chronic Spontaneous Urticaria in Italy: A Narrative Medicine Project to Improve the Pathway of Patient Care. Acta Dermato-Venereologica, 2017, 97, 81-85.	0.6	21
29	Childhood trauma and resilience in psoriatic patients: A preliminary report. Journal of Psychosomatic Research, 2018, 106, 25-28.	1.2	21
30	HLA-Cw6 allele, NFkB1 and NFkBIA polymorphisms play no role in predicting response to etanercept in psoriatic patients. Pharmacogenetics and Genomics, 2016, 26, 423-427.	0.7	20
31	The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapies. Journal of Dermatological Treatment, 2022, 33, 1079-1083.	1.1	20
32	Melanoma onset after estrogen, thyroid, and growth hormone replacement therapy. Clinical Therapeutics, 2010, 32, 57-59.	1.1	19
33	Granuloma faciale: a case report on long-term treatment with topical tacrolimus and dermoscopic aspects. Dermatologic Therapy, 2011, 24, 508-511.	0.8	19
34	Patients' demographic and socioeconomic characteristics influence the therapeutic decision-making process in psoriasis. PLoS ONE, 2020, 15, e0237267.	1.1	19
35	Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert Opinion on Biological Therapy, 2021, 21, 1299-1310.	1.4	19
36	Moderate-to-severe psoriasis and pregnancy: impact on fertility, pregnancy outcome and treatment perspectives. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 305-314.	0.8	19

#	Article	IF	CITATIONS
37	Treatment of psoriasis with etanercept in immunocompromised patients: Two case reports. Journal of International Medical Research, 2016, 44, 67-71.	0.4	18
38	Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy. Dermatology, 2021, 237, 535-541.	0.9	18
39	Cutaneous adverse reactions following <scp>SARSâ€CoV</scp> â€2 vaccine booster dose: a realâ€life multicentre experience. Journal of the European Academy of Dermatology and Venereology, 2022, 36, .	1.3	18
40	Psoriasis Area and Severity Index response in moderateâ€severe psoriatic patients switched to adalimumab: results from the <scp>OPPSA</scp> study. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1737-1744.	1.3	16
41	Role of personalized medication training in improving efficacy and adherence to a topical therapy in psoriatic patients. Journal of Dermatological Treatment, 2017, 28, 722-725.	1.1	15
42	Circumscribed pityriasis rubra pilaris type IV. Clinical and Experimental Dermatology, 2007, 32, 471-472.	0.6	13
43	Psychopathology and eating disorders in patients with psoriasis. Giornale Italiano Di Dermatologia E Venereologia, 2014, 149, 355-61.	0.8	13
44	Risankizumab for the treatment of moderateâ€toâ€severe psoriasis: A multicenter, retrospective, 1 year realâ€life study. Dermatologic Therapy, 2022, 35, e15489.	0.8	13
45	Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practice. Expert Opinion on Biological Therapy, 2021, 21, 279-286.	1.4	12
46	Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience. Acta Dermato-Venereologica, 2020, 100, adv00172.	0.6	12
47	Development of pemphigus vulgaris in a patient with psoriasis treated with cyclosporine. Journal of the American Academy of Dermatology, 2010, 63, 356-357.	0.6	11
48	Tildrakizumab in moderateâ€ŧoâ€severe plaque psoriasis: A multicenter, retrospective, realâ€life study. Dermatologic Therapy, 2022, 35, e15488.	0.8	11
49	Dyshidrosiform pemphigoid: a well-defined clinical entity?. European Journal of Dermatology, 2011, 21, 112-113.	0.3	10
50	Dermoscopy of Melanocytic Lesions in Patients Affected by Oculocutaneous Albinism: A Case Series. Dermatology, 2013, 226, 358-361.	0.9	10
51	Linear IgA bullous dermatosis andÂulcerative colitis treated byÂproctocolectomy. European Journal of Dermatology, 2009, 19, 651-651.	0.3	10
52	Multiple paradoxical reactions during ixekizumab therapy. Dermatologic Therapy, 2019, 32, e12852.	0.8	9
53	Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life. European Journal of Dermatology, 2019, 29, 192-196.	0.3	9
54	Enteric-coated mycophenolate sodium as a steroid-sparing agent in pemphigus treatment: a retrospective study. Dermatologic Therapy, 2012, 25, 219-222.	0.8	8

GIACOMO CALDAROLA

#	Article	IF	CITATIONS
55	Lichen sclerosus of the glans simulating melanoma. Journal of the American Academy of Dermatology, 2017, 76, S49-S51.	0.6	8
56	New JAK inhibitors for the treatment of psoriasis and psoriatic arthritis. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 411-420.	0.8	8
57	Therapeutic Impact and Management of Persistent Head and Neck Atopic Dermatitis in Dupilumab-Treated Patients. Dermatology, 2022, 238, 717-724.	0.9	8
58	Biological agents targeting interleukin-13 for atopic dermatitis. Expert Opinion on Biological Therapy, 2022, 22, 651-659.	1.4	8
59	Linear atrophoderma of Moulin. European Journal of Dermatology, 2008, 18, 79-80.	0.3	8
60	A Possible Role of Polycystic Ovary Syndrome for Pregnancy Complications in Women with Psoriasis. Drug Development Research, 2014, 75, S64-6.	1.4	7
61	A case of linear immunoglobulin A bullous dermatosis in a patient exposed to sun and an analgesic. Clinical Therapeutics, 2009, 31, 1987-1990.	1.1	6
62	Management of Recurrent Cutaneous Abscesses During Therapy With Infliximab. Clinical Therapeutics, 2011, 33, 1993-1996.	1.1	6
63	Multiple eruptive plaqueâ€like dermatofibromas during antiâ€TNFα treatment. International Journal of Dermatology, 2013, 52, 638-641.	0.5	6
64	Psoriasis and polycystic ovary syndrome: a new link in different phenotypes. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 191, 101-105.	0.5	6
65	Certolizumab for the treatment of psoriasis and psoriatic arthritis: a realâ€world multicentre Italian study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 2839-2845.	1.3	6
66	Recalcitrant Sweet Syndrome successfully treated with adalimumab. JDDG - Journal of the German Society of Dermatology, 2021, 19, 122-124.	0.4	6
67	Free and total vitamin D in psoriatic patients treated with biological drugs. Experimental Dermatology, 2021, 30, 995-996.	1.4	5
68	Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in Italy. Expert Opinion on Biological Therapy, 2021, 21, 1291-1298.	1.4	5
69	Bullous pemphigoid in a transplant recipient: is this a sign of allograft rejection?. European Journal of Dermatology, 2012, 22, 280-281.	0.3	5
70	Circulating endothelial cell levels in psoriatic patients and their modification after an antiâ€TNFâ€elpha (Etanercept) treatment. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 590-596.	1.3	4
71	Anti-TNF-α-induced psoriasiform lesions in IBD: an abnormal immune activation or a â€~patchy cutaneous' immune suppression?. Gut, 2014, 63, 699-701.	6.1	4
72	A glass of red wine to keep vascular disease at bay, but what about pemphigus vulgaris?. Expert Review of Clinical Immunology, 2011, 7, 187-191.	1.3	3

GIACOMO CALDAROLA

#	Article	IF	CITATIONS
73	Clinico-dermoscopic features of alopecia areata in patients with psoriasis. JAAD Case Reports, 2018, 4, 665-668.	0.4	3
74	Ixekizumab exposure associated with myelitis: A case report and a literature review. Journal of Neuroimmunology, 2021, 361, 577726.	1.1	3
75	Human leukocyte antigenâ€B*58:01 allele in a familial case of Stevens–Johnson syndrome induced by allopurinol. Journal of Dermatology, 2015, 42, 753-754.	0.6	2
76	A case of chronic disseminated lupus erythematosus in a psoriatic patient receiving ustekinumab. Giornale Italiano Di Dermatologia E Venereologia, 2020, 155, 699-701.	0.8	2
77	Severe and resistant palmar psoriasis successfully treated with risankizumab. Italian Journal of Dermatology and Venereology, 2022, 157, .	0.1	2
78	Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL): a possible pathogenic role in chronic plaque psoriasis. Giornale Italiano Di Dermatologia E Venereologia, 2016, 151, 17-24.	0.8	2
79	Mechanisms of Acantholysis in Pemphigus: Mechanical or Inflammatory?. European Journal of Inflammation, 2006, 4, 77-81.	0.2	1
80	Etanercept Therapy for Psoriasis in a Patient with Numerous Comorbidities. American Journal of Clinical Dermatology, 2010, 11, 49-50.	3.3	1
81	P.04.21 RISK FACTORS FOR PROGRESSION OF LIVER DISEASE IN NAFLD PATIENT WITH PSORIASIS: A COHORT STUDY. Digestive and Liver Disease, 2019, 51, e181-e182.	0.4	0
82	Annular elastolytic giant cell granuloma following herpes zoster infection. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e334-e335.	1.3	0